transdermal glp-1 receptor agonist patch clinical trial Do Patches Really Work? Evidence and FDA-Approved Alternatives GLP-1 receptor agonists and next-generation

Together, this meant more blood sugar control and fewer sugar cravings in mice

Andreozzi F, Raciti GA, Nigro C, et al

In a number of studies, GLP-1R agonists such as liraglutide, exenatide and lixisenatide can reduce neuroinflammation in AD models, thereby improving cognitive dysfunction (140, 141, 144148)

[DOI] [PubMed] [Google Scholar] 119.Caruso I., Cignarelli A., Natalicchio A., Perrini S., Laviola L., Giorgino F

Read more: To view or add a comment, sign in A new study presented at the European Society of Cardiology Congress 2025, powered by Truveta Data from more than 200,000 patients, found: Early discontinuation was linked to higher cardiovascular risks